19:47 , Feb 15, 2019 |  BC Week In Review  |  Company News

Indivior divests Suboxone tablets to China’s Zhejiang Pukang

Indivior plc (LSE:INDV) will sell Chinese rights to its sublingual tablet formulation of Suboxone buprenorphine/naloxone to Zhejiang Pukang Biotechnology Co. Ltd. (Hangzhou, China) so that Indivior can focus on long-term growth of its extended release...
19:27 , Dec 21, 2018 |  BC Week In Review  |  Company News

Orexo regains ex-U.S. rights to Zubsolv from Mundipharma

Orexo AB (SSE:ORX) will regain global, ex-U.S. rights to Zubsolv buprenorphine/naloxone from Mundipharma International Ltd. (Dublin, Ireland), effective April 13. Orexo, which holds U.S. rights to the drug, said the news follows a portfolio reorganization...
18:27 , Nov 30, 2018 |  BC Week In Review  |  Company News

Dr. Reddy's gets green light to market opioid dependence generic

Dr. Reddy's Laboratories Ltd. (NYSE:RDY) said on Nov. 20 that a U.S. federal court vacated a district court's preliminary decision that prohibited the company from selling its generic version of film Suboxone buprenorphine/naloxone sublingual from...
17:28 , Sep 14, 2018 |  BC Week In Review  |  Company News

ICER finds opioid use disorder treatments not cost-effective

In a draft evidence report, ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value of...
23:10 , Sep 10, 2018 |  BC Extra  |  Company News

ICER finds opioid use disorder treatments are not cost-effective

In a draft evidence report , ICER found that newer extended-release formulations of medication-assisted treatments (MATs) for opioid use disorder were not cost-effective compared with generic medicines. The institute compared the clinical effectiveness and value...
20:44 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA approves Suboxone generics from Mylan, Dr. Reddy

FDA approved two generic buprenorphine/naloxone sublingual film products from Mylan N.V. (NASDAQ:MYL) and Dr. Reddy's Laboratories Ltd. (NYSE:RDY), respectively, to treat opioid dependence. FDA said they are the first approved generic versions of Suboxone sublingual...
21:20 , Jun 7, 2018 |  BC Extra  |  Politics & Policy

NIH prompts formal review of medication-assisted treatment for opioid addiction

In response to a congressional request, NIH has asked the National Academies of Sciences, Engineering, and Medicine (NASEM) to review evidence on medication-assisted treatments (MATs) for opioid use disorder to identify knowledge gaps where additional...
15:44 , May 4, 2018 |  BC Week In Review  |  Company News

ICER to consider broad outcomes for buprenorphines

In a draft scoping document published April 26, ICER said it will consider a broad set of outcomes in its review of three buprenorphine products as medication-assisted treatments for opioid use disorder. ICER is poised...
21:37 , Apr 27, 2018 |  BC Extra  |  Politics & Policy

ICER to consider broad outcomes for buprenorphines

In a draft scoping document published Thursday, ICER said it will consider a broad set of outcomes in its review of three buprenorphine products as medication-assisted treatments for opioid use disorder. ICER is poised to...
17:10 , Apr 6, 2018 |  BC Week In Review  |  Company News

ICER to evaluate buprenorphines for opioid disorder

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder. In...